Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,077 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients.
Lodde G, Forschner A, Hassel J, Wulfken LM, Meier F, Mohr P, Kähler K, Schilling B, Loquai C, Berking C, Hüning S, Schatton K, Gebhardt C, Eckardt J, Gutzmer R, Reinhardt L, Glutsch V, Nikfarjam U, Erdmann M, Stang A, Kowall B, Roesch A, Ugurel S, Zimmer L, Schadendorf D, Livingstone E. Lodde G, et al. Among authors: schadendorf d. Cancers (Basel). 2021 May 12;13(10):2319. doi: 10.3390/cancers13102319. Cancers (Basel). 2021. PMID: 34065995 Free PMC article.
Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC, Steinle A, Schadendorf D, Ugurel S. Paschen A, et al. Among authors: schadendorf d. Clin Cancer Res. 2009 Aug 15;15(16):5208-15. doi: 10.1158/1078-0432.CCR-09-0886. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671853
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
Hauschild A, Weichenthal M, Rass K, Linse R, Berking C, Böttjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Stein A, Näher H, Schadendorf D, Mohr P, Kaatz M, Tronnier M, Hein R, Schuler G, Egberts F, Garbe C. Hauschild A, et al. Among authors: schadendorf d. J Clin Oncol. 2010 Feb 10;28(5):841-6. doi: 10.1200/JCO.2009.23.1704. Epub 2010 Jan 4. J Clin Oncol. 2010. PMID: 20048184 Clinical Trial.
PLX4032: does it keep its promise for metastatic melanoma treatment?
Livingstone E, Zimmer L, Piel S, Schadendorf D. Livingstone E, et al. Among authors: schadendorf d. Expert Opin Investig Drugs. 2010 Nov;19(11):1439-49. doi: 10.1517/13543784.2010.527945. Epub 2010 Oct 14. Expert Opin Investig Drugs. 2010. PMID: 20942773 Review.
Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma.
Eigentler TK, Figl A, Krex D, Mohr P, Mauch C, Rass K, Bostroem A, Heese O, Koelbl O, Garbe C, Schadendorf D; Dermatologic Cooperative Oncology Group and the National Interdisciplinary Working Group on Melanoma. Eigentler TK, et al. Among authors: schadendorf d. Cancer. 2011 Apr 15;117(8):1697-703. doi: 10.1002/cncr.25631. Epub 2010 Nov 8. Cancer. 2011. PMID: 21472716 Free article.
Current advances and perspectives in the treatment of advanced melanoma.
Livingstone E, Zimmer L, Vaubel J, Schadendorf D. Livingstone E, et al. Among authors: schadendorf d. J Dtsch Dermatol Ges. 2012 May;10(5):319-25. doi: 10.1111/j.1610-0387.2012.07895.x. Epub 2012 Mar 20. J Dtsch Dermatol Ges. 2012. PMID: 22432863 Free article. Review.
1,077 results